Roche has announced that it has discontinued Zenapax (daclizumab sterile concentrate for injection), an IgG1 monoclonal antibody. The decision to discontinue Zenapax is due to the diminishing market demand and the availability of alternative treatments and is not due to any safety issue. The existing supply of Zenapax is expected to be depleted by January 2010 based on current demand. The last lots of Zenapax available in the U.S. will expire in 2011.
Zenapax is indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.
For more information call (800) 526-6367 or visit www.roche.com.